Abstract: Supramolecular complexes that target and cleave DNA are provided. The supramolecular complexes include at least one metal-to-ligand charge transfer (MLCT) light absorbing unit, at least one Pt based DNA binding unit, and at least one bridging unit that serves to connect the components. The Pt-based DNA binding unit binds the complex to DNA, and the MLCT unit absorbs light, thereby sensitizing molecular oxygen to produce reactive oxygen species in close proximity to the complex and the bound DNA. The reactive oxygen species cleave the bound DNA.

Abstract: In a general formula (1), each of R1 and R2 represents any one of hydrogen, an alkyl group, a halogen group, —CF3, an alkoxy group, and an aryl group. M represents an element that belongs to Group 9 or Group 10. Here, an alkyl group having 1 to 4 carbon atoms is preferable in the alkyl group. A fluoro group is particularly preferable in the halogen group. An alkoxy group having 1 to 4 carbon atoms is preferable in the alkoxy group. A phenyl group is particularly preferable in the aryl group. Iridium is particularly preferable among the elements that belong to Group 9, and platinum is particularly preferable among the elements that belong to Group 10. The general formula (1) is inserted.

Abstract: Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.

Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.

Abstract: Described are novel platinum (II) containing organometallic materials. These materials show green to orange emissions with high emission quantum efficiencies. Using the materials as emitting materials; pure green emitting organic light-emitting diodes can be fabricated. Since the novel platinum (II) containing organometallic materials are soluble in common solvents, solution process methods such as spin coating and printing can be used for device fabrication.

Abstract: The present invention relates to an electronic device, in particular an organic electroluminescent device, which comprises metal complexes containing azaborole ligands. The invention also relates to the metal complexes themselves, to the use thereof in an organic electronic device, and to a process for the preparation thereof. Finally, the invention is directed to the ligands and to the use of the ligands for the preparation of the metal complexes according to the invention.

Abstract: An organometallic complex comprising a moiety represented by the following general formula (1). The organometallic complex is applied to a light-emitting element, and a light-emitting device reduced in power consumption is manufactured by using the light-emitting element.

Abstract: Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled triamino-pyridine derivatives, methods of synthesizing these compounds, intermediate compounds, methods of treatment using these compounds, methods of imaging, diagnosing, localizing, monitoring, and/or assessing a condition (e.g., corticotropin releasing factor type-1 (CRF1)) and/or related biological events, using triamino-pyridine derivatives, and the like. In addition, the present disclosure includes compositions (e.g., labeled triamino-pyridine derivatives that are ligands for the CRF1 receptor) used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging or SPECT imaging).

Abstract: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C1 to C16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N.

Abstract: The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes.

Abstract: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.

Abstract: In a general formula (1), each of R1 and R2 represents any one of hydrogen, an alkyl group, a halogen group, —CF3, an alkoxy group, and an aryl group. M represents an element that belongs to Group 9 or Group 10. Here, an alkyl group having 1 to 4 carbon atoms is preferable in the alkyl group. A fluoro group is particularly preferable in the halogen group. An alkoxy group having 1 to 4 carbon atoms is preferable in the alkoxy group. A phenyl group is particularly preferable in the aryl group. Iridium is particularly preferable among the elements that belong to Group 9, and platinum is particularly preferable among the elements that belong to Group 10. The general formula (1) is inserted.

Abstract: Provided is a cyclometalated transition metal complex represented by Formula 1: The cyclometalated transition metal complex contains a new ancillary ligand having a carboxylate acid or the like connected to a hetero ring, so that it can efficiently emit red light from a phosphorous material through intersystem crossing (ISC) to form triplet excitons and then metal to ligand charge transfer (MLCT). An organic light emitting device manufactured using the transition metal complex shows excellent luminous efficiency and external quantum efficiency.

Abstract: An organometallic complex with high emission efficiency and an organic light-emitting element having the organometallic complex are described. The organometallic complex has a structure represented by the following general formula (G1?).

Abstract: The present invention relates to simultaneous tracking or imaging followed by hyperthermia therapy for cancer and other diseases associated with altered metabolic enzymes. In particular, the invention relates to a novel class of therapeutic nanomaterial which selectively target and kill tumor cells.

Abstract: A large single crystal of a complex such as an organic carboxylic acid metal complex, which crystal is useful as an adsorbent of various gases and vapors of organic solvents and as a hydrogen-absorbing material, as well as a process for producing the crystal, is disclosed. Two layers wherein an upper layer thereof is constituted by a solution containing a metal salt and an organic carboxylic acid having a conjugated system, or a solution containing a metal salt of the organic carboxylic acid having a conjugated system, and wherein a lower layer of the two layers is constituted by a solvent which is not miscible with the solvent of the solution, is formed. Vapor of pyrazine or a substituted pyrazine from a solution of pyrazine or the substituted pyrazine is introduced into the upper layer to allow reaction, thereby forming a large single crystal(s) of the organic carboxylic acid metal complex at the interface between the two layers, which crystal(s) has(have) a longer side with a size of not less than 0.8 mm.

Abstract: An object is to provide a novel organometallic complex capable of emitting phosphorescence by using, as a ligand, an organic compound with which a variety of derivatives can be easily synthesized. Another object is to provide an organometallic complex having high heat resistance. Other objects are to provide a light-emitting element having high emission efficiency and to provide a light-emitting device, an electronic device, and a lighting device having reduced power consumption. Provided are an organometallic complex including a structure represented by the following General Formula (G1), and a light-emitting element, a light-emitting device, an electronic device, and a lighting device formed using the organometallic complex including the structure represented by the following General Formula (G1).

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: The invention provides compounds that comprise a 4?-thio nucleoside that is a derivative of 4?-thiothymidine or 4?-thio-2?-deoxyuridine comprising a positron or single photon emitting radioisotope or corresponding non-radioactive isotope attached via a triazole link to the N-3 position. Methods for preparing such compounds and uses of the compounds in medicine are also provided.

Abstract: Novel organic compounds containing a twisted aryl group are provided. In particular, the compounds provided contain a 2-phenylpyridine ligand having a twisted aryl group on the pyridine portion of the ligand. The compounds may be used in organic light emitting devices, particularly as emitting dopants. Devices comprising the compounds containing twisted aryl may demonstrate improved color, efficiency, stability and manufacturing. Additionally, methods are provided for making homoleptic Ir (III) compounds which may contain a twisted aryl.

Abstract: Compounds comprising a 2-phenylpyridine ligand further substituted with a heterocyclic group are provided. In particular, the compound comprises a 2-phenylpyridine ligand further substituted with a nitrogen-containing heterocycle. The compounds may be used in organic light emitting devices to provide devices having improved efficiency and lifetime.

Abstract: The use of nanoparticles for imaging a tumour in a mammal using electrical impedance tomography. The nanoparticles comprise a core of metal and/or semiconductor atoms to which are linked ligands that comprise a molecule capable of attaching to a specific tumour biomarker.

Abstract: Disclosed is a compound characterized by comprising a linker, an oxygen-concentration-responsive phosphorophore which is linked to a first end of the linker, and a fluorophore which is lined to a second end of the linker. In the compound, it is preferred that the triplet level of the phosphorophore be lower than that of the fluorophore. The compound can be used as an oxygen-responsive luminescent probe.

Abstract: It is an object of the present invention to provide a substance capable of emitting phosphorescence. In addition, it is an object of the present invention to provide a light-emitting element that is excellent in chromaticity. One aspect of the present invention is an organometallic complex having a structure represented by a general formula (1). In the general formula (1), R1 to R4 are each any one of hydrogen, a halogen element, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a cyano group, and a heterocyclic group. In addition, R5 to R13 are each any one of hydrogen, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a heterocyclic group, and an electron-withdrawing group. An organometallic complex having such a structure can emit phosphorescence with higher emission intensity.

Abstract: A Copper (I) chloride complex of pyrazinic acid having the empirical formula C10H12ClCuN4O6 is prepared, further characterized by its crystal structure, described as “CuCl (pyrazinic acid)2.2H2O”, or “CuCl (pyrazinic acid)2.H2O” and more fully detailed as attached hereto. This compound is effective to cure or ameliorate, when mixed into a pharmaceutically acceptable composition, certain otherwise intractable diseases, e.g. myopathy or weakness of muscles in general, infertility, and certain genetically caused disorders in mammals. It also enhances regeneration of tissue affected by burns and scars, improves alopecia, decreases blood lipids and helps in loss of weight in obese patients. The wide scope of activities is probably due to stem cell stimulation, enhancement of the immune system and role of copper-dependent enzyme activity.

Abstract: The present invention relates to an organic electroluminescence device containing a light emitting metallic compound of Chemical Formula 1. In the Chemical Formula 1, M is selected from Ir, Pt, Rh, Re, and Os, and m is 2, provided that m is 1 when M is Pt.

Abstract: The present invention relates to reducible porous crystalline solids, constituted of a metal-organic framework (MOF), for the separation of mixtures of molecules having different unsaturation degrees and/or a different number of unsaturations with a selectivity that can be adjusted by controlling the reduction of the MOF. The MOF solids of the present invention, after reduction, have a strong affinity for molecules containing at least one unsaturation. They can be used in various separation processes, especially those relating to hydrocarbons.

Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: An organometallic complex according to the present invention comprises a structure represented by the following general formula (1). In the formula, R1 to R5 are any one selected from the group consisting of hydrogen, a halogen element, an acyl group, an alkyl group, an alkoxy group, an aryl group, a cyano group, and a heterocyclic group, Ar is an aryl group having an electron-withdrawing group or a heterocyclic group having electron-drawing group, and M is an element of Group 9 or an element of Group 10.

Abstract: Provided are a saturated N-heterocyclic carbene-ligand metal complex derivative, a method for preparing the same, and a method for preparing a silane compound by hydrosilylation using the same as a catalyst. To describe in more detail, the metal complex derivative has a saturated N-heterocyclic carbene derivative and an olefin ligand at the same time. A silane compound is prepared by hydrosilylation in the presence of the metal complex derivative as a catalyst. The provided metal complex derivative of the present invention has superior stability during hydrosilylation reaction and is capable of effectively performing the hydrosilylation reaction at low temperature even with small quantity. Further, a product with superior regioselectivity may be obtained. In addition, after the hydrosilylation reaction is completed, the metal complex derivative may be recovered and recycled.

Abstract: The present invention provides unimolecular metal complexes having increased activity in the copolymerization of carbon dioxide and epoxides. Also provided are methods of using such metal complexes in the synthesis of polymers. According to one aspect, the present invention provides metal complexes comprising an activating species with co-catalytic activity tethered to a multidentate ligand that is coordinated to the active metal center of the complex.

Abstract: The invention provides novel synthetic intermediates and processes that can be used to prepare compounds of formula (I), wherein R1 has any of the values described herein and R2 is a nucleoside sugar group.

Abstract: The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to novel ionic liquid compositions.

Abstract: Heteromolecular metal-humic organic complexes of the type: (A)n-(Metal)x-(B)m where A is one or several humic complexes which may be totally or partially sulfonated or may have been treated with an amine in order to protect the carboxylic groups from interacting with polyvalent cations, and B is a non-humic complexing (organic chelating agent) compound, the biological and chemical stability whereof allows for protection of the metal and the multitoothed or multi-valent molecule involved in the complex against degradation phenomena, both chemical and microbiological, having the beneficial effect of humic acid, as an effective plant growth and nutrition stimulant and as a metabolic and immune system activator in animals and humans.

Abstract: It is an object of the present invention to provide a substance which can emit red phosphorescence which is closer to the chromaticity coordinates of red according to the NTSC standard. The present invention provides an organometallic complex represented by the general formula (1), wherein each of R1 to R3 represents any one of hydrogen, a halogen group, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a cyano group, and a heterocyclic group, and at least one of R1 to R3 represents an electron-withdrawing group; and M represents a Group 9 element or a Group 10 element, and when M is the Group 9 element, n=2, whereas when M is the Group 10 element, n=1. Such an organometallic complex can emit red phosphorescence with good spectral luminous efficiency which is closer to the chromaticity coordinates of red according to the NTSC standard.

Abstract: The present invention relates to a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.

Abstract: The present invention provides methods for the synthesis of catalysts and precursors thereof. Methods of the invention may comprise combining a catalyst precursor and at least one ligand to generate a catalytically active species, often under mild conditions and in high yields. In some cases, a wide variety of catalysts may be synthesized from a single catalyst precursor. Methods of the invention may also include the preparation of catalysts which, under reaction conditions known in the art, may have been difficult or impossible to prepare and/or isolate due to, for example, steric crowding at the metal center. The present invention also provides catalyst compositions, and precursors thereof, which may be useful in various chemical reactions including olefin metathesis. In some cases, methods of the invention may reduce the number of synthetic and purification steps required to produce catalysts and/or other reaction products, as well as reducing time, cost, and waste production.

Abstract: This invention relates to electroluminescent metal complexes of the formula (I), or (II), a process for their preparation, electronic devices comprising the metal complexes and their use in electronic devices, especially organic light emitting diodes (OLEDs), as oxygen sensitive indicators, as phosphorescent indicators in bioassays, and as catalysts.

Abstract: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C1 to C16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N.

Abstract: An object is to provide a novel organometallic complex capable of emitting phosphorescence, an organometallic complex which exhibits deep red emission, and a light-emitting element which provides deep red emission. Provided is an organometallic complex having a structure represented by the following General Formula (G1). In the formula, R1, R2, R3, R4, R5, R6, R7, R8, and R9 represent substituents, and M is a central metal and represents either a Group 9 element or a Group 10 element.

Abstract: Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1?,2?-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.

Abstract: The present invention relates to copper-organic complexes and pharmaceutical compositions containing the same. They can be used especially in the treatment of diseases caused by hyperproliferative cells and, in addition, protect healthy tissue from ionizing radiation. They are prepared by reacting a copper(II) acylate with an organic compound selected from 4-[bis(2-chloroethyl)amino]-D,L-phenyl-alanine (sarcolysine), the hydrochloride thereof, N-(2-furanidil)-5-fluorouracil (tegafur) and aminocarbonylaziridine (leacadin) at acidic to neutral pH in a chloroform/methanol mixture.

Abstract: An organometallic complex according to the present invention comprises a structure represented by the following general formula (1). In the formula, R1 to R5 are any one selected from the group consisting of hydrogen, a halogen element, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a cyano group, and a heterocyclic group, Ar is an aryl group having an electron-withdrawing group or a heterocyclic group having electron-drawing group, and M is an element of Group 9 or an element of Group 10.

Abstract: Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1?,2?-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.

Abstract: The present invention relates to processes for preparing a porous metal-organic framework comprising at least two organic compounds coordinated to at least one metal ion, the porous metal-organic frameworks prepared by the process and their use, in particular for gas storage and gas separation.

Abstract: The present invention provides a chiral inorganic-organic composite porous material in which cationic chiral organic molecules are present as charge-balancing cations in a porous material containing charge-balancing cations, as well as a method for preparing the same by an ion exchange process. The chiral inorganic-organic composite porous material according to the present invention is excellent in stability, selectivity and durability, and thus, will be useful as a chiral-selective catalyst or a material of separating an isomeric mixture.

Abstract: The present invention provides a catalyst complex or ligand, and compositions thereof, for use in a variety of organic reactions having high reactivity and enantioselectivity. The catalyst is a N-heterocyclic carbene having three fused rings with first and second rings being six-membered rings and the third being a five-membered ring. The first ring is fused to the second and has four substituents. The second ring has two nitrogens flanking a carbene atom with one nitrogen bound to a substituent. The carbene atom may optionally be bonded to a metal. The third ring is fused to the second ring and contains two nitrogens. The third ring of the catalyst has a double bond and two substituents on adjacent non-fused carbons. A non-fused nitrogen of the third ring is partially bonded to another substituent. Methods for the synthesis and use of the catalyst embodiments of the present invention are also provided.

Abstract: The present invention provides ruthenium or osmium complexes and their uses as a catalyst for catalytic water oxidation. Another aspect of the invention provides an electrode and photo-electrochemical cells for electrolysis of water molecules.

Abstract: The present invention relates to the use of dithiocarbamate compounds and to an assembly for use in an electronic device, said assembly comprising a self-assembled monolayer of at least one dithiocarbamate compound. The present invention also relates to an electronic device including such assembly.